Abstract
HSR24-142: Real-World Clinical Benefit Among Patients (pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have